Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Br J Haematol ; 198(5): 916-922, 2022 09.
Article in English | MEDLINE | ID: mdl-35701886

ABSTRACT

Thrombopoietin receptor agonists (TPO-RA) are a valid therapy for immune thrombocytopenia (ITP), due to megakaryocyte stimulation and (poorly characterised) immune-modulatory effects. The spleen is pivotal in the pathogenesis of ITP, yet little is known on its immune microenvironment and on effects of TPO-RA on this organ. To address these topics, we analysed 35 spleens removed for primary refractory ITP. Pre-splenectomy TPO-RA administration correlated with increased splenic regulatory T cells (Tregs), type 2 T-helper cells and histiocyte density and with reduced red pulp sinusoids. Surgical outcome was not associated with TPO-RA administration, other pre-splenectomy therapies and/or Treg density. In conclusion, TPO-RA affect the splenic microenvironment, but this has no impact on splenectomy outcome.


Subject(s)
Purpura, Thrombocytopenic, Idiopathic , Thrombocytopenia , Humans , Purpura, Thrombocytopenic, Idiopathic/etiology , Receptors, Fc , Receptors, Thrombopoietin/agonists , Recombinant Fusion Proteins , Spleen/pathology , T-Lymphocytes, Regulatory/pathology , Thrombocytopenia/complications , Thrombopoietin/pharmacology , Thrombopoietin/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL